These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection. Thistlethwaite JR; Stuart JK; Mayes JT; Gaber AO; Stuart FP Am J Kidney Dis; 1988 Feb; 11(2):94-8. PubMed ID: 3277413 [TBL] [Abstract][Full Text] [Related]
11. OKT3 for primary therapy of the first rejection episode in kidney transplants. Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875 [TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063 [TBL] [Abstract][Full Text] [Related]
13. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990 [TBL] [Abstract][Full Text] [Related]
14. Immunologic monitoring with Orthoclone OKT3 therapy. Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358 [TBL] [Abstract][Full Text] [Related]
15. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial. Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510 [TBL] [Abstract][Full Text] [Related]
16. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Steinmuller DR; Hayes JM; Novick AC; Streem SB; Hodge E; Slavis S; Martinez A; Graneto D; Pearce G Transplantation; 1991 Jul; 52(1):67-71. PubMed ID: 1677502 [TBL] [Abstract][Full Text] [Related]
17. Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection. Hricik DE; Zarconi J; Schulak JA Transplantation; 1989 Feb; 47(2):272-7. PubMed ID: 2493175 [TBL] [Abstract][Full Text] [Related]
18. OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients. Carreno M; Yang WC; Esquenazi V; Fuller L; Burke G; Milgrom M; Roth D; Ranjan D; Miller J Transplantation; 1990 Feb; 49(2):408-15. PubMed ID: 1689519 [TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Shield CF; Jacobs RJ; Wyant S; Das A Am J Kidney Dis; 1996 Jun; 27(6):855-64. PubMed ID: 8651251 [TBL] [Abstract][Full Text] [Related]
20. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]